A Phase 3 interventional study of Dupilumab in Asthma, sponsored by Sanofi. Completed at 365 sites in 27 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one has the largest enrollment, is the only one that started in 2014, is one of 11 in phase 3, and was the 3rd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2014.
This study's enrollment of 2,282 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one has the largest enrollment of the 31 interventional ones that give a count, is the only one that started in 2014, is one of 16 in phase 3, and was the 12th registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691).
Secondary Objectives:
To evaluate the long-term efficacy of dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study.
To evaluate dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study, with regards to:
A screening period, up to 3 weeks, applied only for participants who came from DRI12544 study. The total study duration, per participant, was a maximum of 108 weeks (or 111 weeks considering a maximum screening period of 3 weeks for study DRI12544) for the participants enrolled prior to Amendment 04 approval and a maximum of 60 weeks for the participants enrolled after Amendment 04 approval.
Following amendment 04 (dated 31 Oct 2016) the open-label treatment duration was amended to 48 weeks (1 year); and the 16-week post-treatment period was shortened to 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1\* Dose every 2 weeks added to current controller medications. For participants coming from other studies: dupilumab 1 \* Dose SC every 2 weeks added to current controller medications.
Drug: Dupilumab
Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
Also known as: SAR231893, REGN668
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment emergent AE period (time from first dose of investigational medicinal product \[IMP\] in LTS12551 up to the last dose of dupilumab plus 14 weeks). A Serious AE (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities During the TEAE Period
Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP): Less than or equal to (≤) 95 Adults (≤90 Adolescents) millimeters of mercury (mmHg) and decrease from baseline (DFB) greater than or equal to (≥) 20 mmHg; ≥ 160 Adults (≥ 119 Adolescents) mmHg and increase from baseline (IFB) ≥ 20 mmHg. * Diastolic blood pressure (DBP): ≤ 45 Adults (≤54 Adolescents) mmHg and DFB ≥ 10 mmHg; ≥ 110 Adults (≥78 Adolescents) mmHg and IFB ≥ 10 mmHg. * Heart rate (HR): ≤ 50 beats per minute (bpm) and DFB ≥ 20 bpm; ≥ 120 bpm and IFB ≥ 20 bpm. * Respiratory rate: less than (\<) 12 breaths/min(b/m); greater than (\>) 20 b/m. * Weight (kg): ≥ 5 percent (%) DFB; ≥ 5% IFB. * Temperature: ≥ 38.0 degree Celsius (°C) rectal/ear/temporal; ≥ 37.5°C oral; ≥ 37.2°C axillary. TEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.
Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters (Red Blood Cells [RBCs], Platelets and Coagulation) During the TEAE Period
Criteria for potentially clinically significant abnormalities: * Hemoglobin (Hb): ≤ 115 grams per liter (g/L)(Male \[M\]), ≤ 95 g/L (Female\[ F\]) (\< 100 g/L Adolescents); ≥ 185 g/L (M), ≥ 165 g/L (F) (≥ 200 g/L Adolescents); DFB ≥ 20 g/L. * Hematocrit: ≤ 0.37 volume/volume (v/v) (M); ≤ 0.32 v/v (F) (\<0.32 v/v Adolescents); ≥ 0.55 v/v (M); 0.5 v/v (F) (\>0.47 v/v Adolescents). * RBCs: ≥ 6 Tera/L. * Platelets: \< 100 Giga(G)/L; ≥ 700 G/L. TEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.
Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)
Number of Severe Exacerbation Events
Severe asthma exacerbation events were defined as a deterioration of asthma which required: use of systemic corticosteroids for ≥ 3 days, (participants from study EFC13691 (NCT02528214), and who were taking systemic corticosteroids: the use of systemic corticosteroids at least double the current dose and for ≥3 days.) or, hospitalization or emergency room visit because of asthma, required systemic corticosteroids.
Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)
Annualized Event Rate Per Participant-Years for Severe Exacerbation
The annualized event rate per participant-years was defined as the total number of events that occurred during the treatment period divided by the total number of participant-years during the treatment period.
Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 48 and 96
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Change From Baseline in Percent Predicted FEV1 at Weeks 48 and 96
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Change From Baseline in Forced Vital Capacity (FVC) at Weeks 48 and 96
FVC was a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.
Time frame: Baseline of parent study, Week 48, and Week 96 of this extension study
Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 48 and 96
FEF was the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.
Time frame: Baseline of parent study, Week 48, and Week 96 of this extension study
Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Mean Scores at Weeks 24 and 48
The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total mean score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. For this analysis, baseline was defined as respective parent study baseline.
Time frame: Baseline of parent study, Weeks 24, and 48 of this extension study
Percentage of Participants Achieving ACQ-5 Score Response (ACQ-5 Responders) at Weeks 24 and 48
ACQ-5 response was defined as change from baseline in ACQ-5 scores ≥ 0.5. The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 mean total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time frame: At Weeks 24, and 48 of this extension study
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Scores at Weeks 24 and 48
The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), and environmental stimuli (4 items). Each item was scored on a 7-point likert scale ranged from 1=severely impaired to 7=not impaired. The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired); higher scores indicated better quality of life. For this analysis, baseline was defined as respective parent study baseline.
Time frame: Baseline of parent study, Weeks 24, and 48 of this extension study
Percentage of Participants Achieving AQLQ Global Score Response (AQLQ Responders) at Weeks 24 and 48
AQLQ global response was defined as participants with change from baseline in AQLQ global score ≥ 0.5. The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=severely impaired, 7=not impaired). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired). Higher scores indicated better quality of life.
Time frame: At Weeks 24, and 48 of this extension study
Serum Concentrations of Dupilumab Over Time Till Week 96
For this analysis, baseline was defined as respective parent study baseline. Here, 'number analyzed'=number of participants with available data for each specified category.
Time frame: Baseline of parent study, Weeks 0, 4, 12, 24, 48, 72, and 96 of this extension study
Percentage of Participants With Antidrug Antibodies (ADA) Response
ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose in LTS12551, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as "30 to \> 10,000", where low titer (\< 1,000); moderate (1,000 ≤ titer ≤ 10,000) and high titer (\> 10,000).
Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)
Change From Baseline in Blood Eosinophils Cells Count at Weeks 48 and 96
For this analysis, baseline was defined as respective parent study baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Change From Baseline in Morning Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544
The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Morning PEF was performed within 15 minutes after arising (between 5:30 AM and 10 AM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent study DRI12544 baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Change From Baseline in Evening Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544
The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Evening PEF was performed in the evening (between 5:30 PM and 10 PM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent DRI12544 study baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Change From Baseline in Morning Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0=no asthma symptoms, slept through the night, 1=slept well, but some complaints in the morning. No nighttime awakenings, 2=woke up once because of asthma (including early awakening), 3=woke up several times because of asthma (including early awakening), 4=bad night, awake most of the night because of asthma; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Change From Baseline in Evening Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.
Time frame: Baseline of parent study, Week 48, and Week 96 of this extension study
Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol for Symptom Relief at Weeks 48 and 96: Participants From Study DRI12544
The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations was recorded daily by the participants in an electronic diary/PEF meter. Mean number of inhalations in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.
Time frame: Baseline of parent study, Week 48, and Week 96 of this extension study
Change From Baseline in Number of Nocturnal Awakenings at Weeks 48 and 96: Participants From Study DRI12544
The number of nocturnal awakening because of asthma symptoms were recorded every morning by the participants in an electronic diary. Mean number of awakenings in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Percent Change From Baseline in Oral Corticosteroid (OCS) Dose at Weeks 48, and 96: Participants From Study EFC13691
OCS was allowed as background controller medication for the participants from study EFC13691 only. For this analysis, baseline was defined as parent study EFC13691 baseline.
Time frame: Baseline of parent study, Weeks 48 and 96 of this extension study
Percentage of Participants Achieving a Reduction of 50% or Greater (≥ 50% ) in OCS Dose Over Time at Weeks 48 and 96: Participants From Study EFC13691
OCS was allowed as background controller medication for the participants from study EFC13691 only. Percentage of participants who achieved a reduction of ≥ 50% in OCS dose were reported.
Time frame: Weeks 48 and 96 of this extension study
Percentage of Participants With Background OCS Completely Tapered Off Over Time at Weeks 48 and 96: Participants From Study EFC13691
OCS was allowed as background controller medication for the participants from study EFC13691 only. Number of participants who gradually discontinued or reduced therapeutic dose were reported in this outcome measure.
Time frame: Weeks 48, and 96 of this extension study
Change From Baseline in European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Scores at Weeks 48 and 96: Participants From Study DRI12544
EQ-5D-3L: validated and reliable self-report health status questionnaire consisted of EQ-5D descriptive system and visual analogue scale (VAS). EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem, some problems, and severe problems. The 5 dimensional 3-level systems was converted into single index utility score, and the score was 0 - 100, where 100=best health state; and 0=worst health state; where higher scores indicated better outcome. For this analysis, baseline was defined as parent DRI12544 study baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Change From Baseline in EQ-5D-3L VAS Scores at Weeks 48 and 96: Participants From Study DRI12544
EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. For this analysis, baseline was defined as parent DRI12544 study baseline.
Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study
Study was initiated at 365 sites in 27 countries. Participants who successfully completed treatment in studies DRI12544 (NCT01854047),EFC13579 (NCT02414854),EFC13691 (NCT02528214) and PDY14192 (NCT02573233) were eligible to continue their treatment in this extension study LTS12551. Total of 2282 participants were enrolled and treated in this study.
| Milestone | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Started | 111 | 421 | 517 | 1013 | 97 | 90 | 19 | 14 |
| Completed | 102 | 379 | 465 | 908 | 83 | 76 | 15 | 11 |
| Not completed | 9 | 42 | 52 | 105 | 14 | 14 | 4 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 | 3 | 2 | 1 | 2 | 1 | 0 |
| Withdrew: Poor compliance to protocol | 1 | 1 | 3 | 7 | 1 | 1 | 0 | 0 |
| Withdrew: Other unspecified | 4 | 22 | 33 | 64 | 8 | 6 | 2 | 1 |
| Withdrew: Adverse event | 3 | 19 | 13 | 32 | 4 | 5 | 1 | 2 |
An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment emergent AE period (time from first dose of investigational medicinal product \[IMP\] in LTS12551 up to the last dose of dupilumab plus 14 weeks). A Serious AE (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
| Participants | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Any TEAE | 88 | 369 | 414 | 789 | 74 | 70 | 18 | 13 |
| Any treatment emergent SAE | 14 | 42 | 48 | 106 | 12 | 10 | 0 | 4 |
| Any TEAE leading to death | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Any TEAE leading to permanent discontinuation | 3 | 19 | 12 | 31 | 4 | 5 | 1 | 2 |
Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP): Less than or equal to (≤) 95 Adults (≤90 Adolescents) millimeters of mercury (mmHg) and decrease from baseline (DFB) greater than or equal to (≥) 20 mmHg; ≥ 160 Adults (≥ 119 Adolescents) mmHg and increase from baseline (IFB) ≥ 20 mmHg. * Diastolic blood pressure (DBP): ≤ 45 Adults (≤54 Adolescents) mmHg and DFB ≥ 10 mmHg; ≥ 110 Adults (≥78 Adolescents) mmHg and IFB ≥ 10 mmHg. * Heart rate (HR): ≤ 50 beats per minute (bpm) and DFB ≥ 20 bpm; ≥ 120 bpm and IFB ≥ 20 bpm. * Respiratory rate: less than (\<) 12 breaths/min(b/m); greater than (\>) 20 b/m. * Weight (kg): ≥ 5 percent (%) DFB; ≥ 5% IFB. * Temperature: ≥ 38.0 degree Celsius (°C) rectal/ear/temporal; ≥ 37.5°C oral; ≥ 37.2°C axillary. TEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.
| Participants | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| SBP: ≤ 95 (≤90) & DFB ≥ 20 mmHg | 4 | 12 | 19 | 40 | 0 | 1 | 2 | 0 |
| SBP: ≥ 160 (≥119) & IFB ≥ 20 mmHg | 2 | 17 | 21 | 45 | 6 | 1 | 1 | 3 |
| DBP: ≤ 45 (≤54) & DFB ≥ 10 mmHg | 1 | 1 | 11 | 15 | 0 | 0 | 0 | 0 |
| DBP: ≥ 110 (≥78) & IFB ≥ 10 mmHg | 0 | 4 | 15 | 20 | 2 | 0 | 0 | 0 |
| HR: ≤ 50 & DFB ≥ 20 bpm | 0 | 3 | 2 | 12 | 0 | 0 | 0 | 0 |
| HR: ≥ 120 & IFB ≥ 20 bpm | 0 | 0 | 2 | 5 | 1 | 0 | 0 | 0 |
| Respiratory rate: < 12 b/m | 5 | 17 | 18 | 24 | 4 | 0 | 2 | 3 |
| Respiratory rate: > 20 b/m | 23 | 104 | 88 | 195 | 18 | 12 | 4 | 0 |
| Weight: ≥ 5% DFB | 32 | 106 | 146 | 261 | 22 | 29 | 3 | 3 |
| Weight: ≥ 5% IFB | 45 | 181 | 189 | 378 | 29 | 37 | 8 | 5 |
| Temperature: ≥ 38.0°C | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Temperature: ≥ 37.5°C | 1 | 0 | 9 | 6 | 0 | 0 | 0 | 0 |
| Temperature: ≥ 37.2°C | 3 | 21 | 4 | 16 | 0 | 1 | 0 | 0 |
Criteria for potentially clinically significant abnormalities: * Hemoglobin (Hb): ≤ 115 grams per liter (g/L)(Male \[M\]), ≤ 95 g/L (Female\[ F\]) (\< 100 g/L Adolescents); ≥ 185 g/L (M), ≥ 165 g/L (F) (≥ 200 g/L Adolescents); DFB ≥ 20 g/L. * Hematocrit: ≤ 0.37 volume/volume (v/v) (M); ≤ 0.32 v/v (F) (\<0.32 v/v Adolescents); ≥ 0.55 v/v (M); 0.5 v/v (F) (\>0.47 v/v Adolescents). * RBCs: ≥ 6 Tera/L. * Platelets: \< 100 Giga(G)/L; ≥ 700 G/L. TEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.
| Participants | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Hb: ≤ 115 g/L, ≤ 95 g/L (< 100 g/L) | 2 | 7 | 12 | 29 | 0 | 3 | 0 | 0 |
| Hb: ≥ 185 g/L, ≥ 165 g/L(≥ 200 g/L) | 1 | 3 | 8 | 4 | 2 | 1 | 0 | 0 |
| Hb: DFB ≥ 20 g/L | 13 | 41 | 40 | 118 | 11 | 7 | 0 | 0 |
| Hematocrit: ≤ 0.37 v/v; ≤ 0.32 v/v(<0.32 v/v) | 6 | 19 | 23 | 47 | 3 | 5 | 0 | 0 |
| Hematocrit: ≥ 0.55 v/v; ≥ 0.5 v/v(>0.47 v/v) | 3 | 6 | 26 | 36 | 3 | 3 | 0 | 0 |
| RBCs: ≥ 6 Tera/L | 1 | 5 | 8 | 15 | 0 | 2 | 0 | 1 |
| Platelets: < 100G/ L | 0 | 2 | 2 | 1 | 1 | 0 | 0 | 1 |
| Platelets: ≥ 700 G/L | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Severe asthma exacerbation events were defined as a deterioration of asthma which required: use of systemic corticosteroids for ≥ 3 days, (participants from study EFC13691 (NCT02528214), and who were taking systemic corticosteroids: the use of systemic corticosteroids at least double the current dose and for ≥3 days.) or, hospitalization or emergency room visit because of asthma, required systemic corticosteroids.
| number of events | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Number of Severe Exacerbation Events | 62 | 242 | 234 | 437 | 35 | 41 | 3 | 1 |
The annualized event rate per participant-years was defined as the total number of events that occurred during the treatment period divided by the total number of participant-years during the treatment period.
| exacerbation per participant-years | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Annualized Event Rate Per Participant-Years for Severe Exacerbation | 0.314 | 0.330 | 0.351 | 0.331 | 0.302 | 0.391 | 0.149 | 0.077 |
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.
| liters | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Week 48 | 0.24 ± 0.42 | 0.28 ± 0.45 | 0.34 ± 0.44 | 0.36 ± 0.53 | 0.31 ± 0.50 | 0.33 ± 0.53 | 0.23 ± 0.40 | 0.01 ± 0.21 |
| Week 96 | 0.22 ± 0.44 | 0.27 ± 0.46 | 0.33 ± 0.44 | 0.31 ± 0.47 | 0.36 ± 0.66 | 0.25 ± 0.46 | 0.14 ± 0.41 | 0.01 ± 0.12 |
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.
| percent predicted FEV1 | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Week 48 | 9.21 ± 13.61 | 10.42 ± 14.61 | 11.74 ± 14.27 | 12.16 ± 16.58 | 10.45 ± 15.03 | 12.41 ± 18.27 | 5.88 ± 10.06 | 1.36 ± 8.35 |
| Week 96 | 8.86 ± 14.47 | 10.68 ± 15.10 | 12.53 ± 14.50 | 11.25 ± 14.55 | 13.06 ± 19.57 | 10.00 ± 15.79 | 4.20 ± 9.60 | 2.00 ± 2.83 |
FVC was a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.
| liters | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Week 48 | 0.22 ± 0.45 | 0.25 ± 0.50 | 0.30 ± 0.48 | 0.35 ± 0.60 | 0.29 ± 0.56 | 0.38 ± 0.56 | 0.21 ± 0.42 | 0.05 ± 0.30 |
| Week 96 | 0.16 ± 0.47 | 0.22 ± 0.52 | 0.27 ± 0.48 | 0.25 ± 0.50 | 0.38 ± 0.82 | 0.22 ± 0.42 | 0.08 ± 0.29 | 0.05 ± 0.40 |
FEF was the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.
| liters/second | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Week 48 | 0.27 ± 0.55 | 0.31 ± 0.55 | 0.39 ± 0.57 | 0.39 ± 0.66 | 0.34 ± 0.56 | 0.29 ± 0.66 | 0.23 ± 0.44 | 0.04 ± 0.26 |
| Week 96 | 0.28 ± 0.57 | 0.32 ± 0.55 | 0.38 ± 0.53 | 0.36 ± 0.61 | 0.42 ± 0.64 | 0.27 ± 0.53 | 0.19 ± 0.41 | 0.04 ± 0.14 |
The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total mean score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. For this analysis, baseline was defined as respective parent study baseline.
| score on a scale | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Week 24 | -1.37 ± 0.91 | -1.48 ± 1.10 | -1.61 ± 1.08 | -1.68 ± 1.05 | -1.09 ± 1.10 | -1.15 ± 1.17 | -0.96 ± 1.03 | -0.80 ± 0.46 |
| Week 48 | -1.33 ± 1.07 | -1.57 ± 1.11 | -1.64 ± 1.08 | -1.69 ± 1.08 | -1.21 ± 1.00 | -1.06 ± 1.25 | -0.89 ± 1.02 | -0.87 ± 0.58 |
ACQ-5 response was defined as change from baseline in ACQ-5 scores ≥ 0.5. The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 mean total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
| percentage of participants | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Week 24 | 82.7 | 80.8 | 84.0 | 86.5 | 67.7 | 70.1 | 57.9 | 69.2 |
| Week 48 | 79.0 | 82.3 | 85.7 | 86.7 | 75.6 | 70.5 | 60.0 | 72.7 |
The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), and environmental stimuli (4 items). Each item was scored on a 7-point likert scale ranged from 1=severely impaired to 7=not impaired. The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired); higher scores indicated better quality of life. For this analysis, baseline was defined as respective parent study baseline.
| score on a scale | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|
| Week 24 | 1.07 ± 0.99 | 1.28 ± 1.24 | 1.38 ± 1.15 | 1.38 ± 1.16 | 0.99 ± 1.10 | 0.97 ± 1.26 |
| Week 48 | 1.07 ± 1.13 | 1.40 ± 1.19 | 1.39 ± 1.17 | 1.40 ± 1.18 | 1.06 ± 0.98 | 1.00 ± 1.23 |
AQLQ global response was defined as participants with change from baseline in AQLQ global score ≥ 0.5. The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=severely impaired, 7=not impaired). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired). Higher scores indicated better quality of life.
| percentage of participants | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|
| Week 24 | 67.6 | 73.6 | 77.6 | 77.2 | 64.2 | 61.4 |
| Week 48 | 65.0 | 76.3 | 77.4 | 78.4 | 73.3 | 68.4 |
For this analysis, baseline was defined as respective parent study baseline. Here, 'number analyzed'=number of participants with available data for each specified category.
| nanogram per milliliter (ng/mL) | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Baseline | 0.00 ± 0.000 | 0.00 ± 1990.640 | — | 0.00 ± 2286.888 | — | 0.00 ± 0.000 | — | 0.00 ± 0.000 |
| Week 0 | 0.00 ± 0.000 | 0.00 ± 0.000 | — | 37230.97 ± 73.261 | — | 40754.49 ± 54.858 | — | 52545.41 ± 44.678 |
| Week 4 | 46848.70 ± 43.149 | 40704.77 ± 47.293 | 25847.86 ± 49.371 | 50566.66 ± 55.104 | 25868.25 ± 53.450 | 48295.93 ± 52.655 | 23336.89 ± 50.542 | 56486.58 ± 45.755 |
| Week 12 | 54467.13 ± 50.267 | 48155.26 ± 52.353 | 45406.55 ± 51.399 | 55140.49 ± 53.114 | 44064.95 ± 57.100 | 50904.34 ± 51.233 | 49026.51 ± 41.619 | 55365.35 ± 53.317 |
| Week 24 | 47023.84 ± 51.645 | 49730.56 ± 53.625 | 50984.57 ± 53.744 | 54897.58 ± 54.044 | 57363.72 ± 57.889 | 44219.42 ± 55.383 | 63080.82 ± 51.224 | 60643.16 ± 41.617 |
| Week 48 | 46355.26 ± 52.612 | 45919.75 ± 55.932 | 41867.50 ± 60.345 | 41849.96 ± 62.049 | 36219.47 ± 67.530 | 36564.41 ± 60.959 | 24864.79 ± 58.016 | 53320.11 ± 46.714 |
| Week 72 | 44771.52 ± 56.256 | 46842.64 ± 53.335 | 45628.10 ± 56.232 | 46372.55 ± 57.719 | 60117.76 ± 62.390 | 32029.19 ± 66.785 | 40362.88 ± 55.567 | 26383.90 ± 120.013 |
| Week 96 | 42431.08 ± 59.222 | 42661.18 ± 59.658 | 38908.58 ± 64.633 | 39088.60 ± 62.897 | 49810.65 ± 65.546 | 19030.70 ± 67.237 | 42360.37 ± 49.409 | 56378.01 ± 7.140 |
ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose in LTS12551, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as "30 to \> 10,000", where low titer (\< 1,000); moderate (1,000 ≤ titer ≤ 10,000) and high titer (\> 10,000).
| percentage of participants | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Treatment-emergent ADA | 10.8 | 12.1 | 9.5 | 4.5 | 7.4 | 8.9 | 0 | 7.1 |
| Treatment-boosted ADA | 0 | 0 | 0 | 0 | 1.1 | 0 | 0 | 0 |
For this analysis, baseline was defined as respective parent study baseline.
| 10^9 cells/L | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Week 48 | 0.007 ± 0.475 | -0.041 ± 0.588 | -0.096 ± 0.428 | -0.099 ± 0.360 | 0.098 ± 0.450 | 0.016 ± 0.382 | -0.066 ± 0.181 | -0.026 ± 0.187 |
| Week 96 | -0.074 ± 0.251 | -0.081 ± 0.562 | -0.161 ± 0.391 | -0.114 ± 0.354 | -0.051 ± 0.399 | 0.083 ± 0.642 | -0.103 ± 0.039 | 0.025 ± 0.134 |
The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Morning PEF was performed within 15 minutes after arising (between 5:30 AM and 10 AM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent study DRI12544 baseline.
| liters per minute (L/min) | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | 13.26 ± 76.71 | 22.95 ± 70.06 |
| Week 96 | 13.63 ± 83.88 | 21.69 ± 77.70 |
The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Evening PEF was performed in the evening (between 5:30 PM and 10 PM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent DRI12544 study baseline.
| L/min | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | 4.65 ± 75.00 | 11.97 ± 72.19 |
| Week 96 | 1.16 ± 79.47 | 10.05 ± 79.47 |
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0=no asthma symptoms, slept through the night, 1=slept well, but some complaints in the morning. No nighttime awakenings, 2=woke up once because of asthma (including early awakening), 3=woke up several times because of asthma (including early awakening), 4=bad night, awake most of the night because of asthma; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.
| score on a scale | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | -0.49 ± 0.78 | -0.68 ± 0.79 |
| Week 96 | -0.52 ± 0.90 | -0.76 ± 0.81 |
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.
| score on a scale | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | -0.47 ± 0.81 | -0.72 ± 0.85 |
| Week 96 | -0.49 ± 0.94 | -0.79 ± 0.88 |
The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations was recorded daily by the participants in an electronic diary/PEF meter. Mean number of inhalations in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.
| inhalations per day | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | -0.00 ± 3.65 | 0.68 ± 4.80 |
| Week 96 | -0.14 ± 4.17 | -0.82 ± 5.18 |
The number of nocturnal awakening because of asthma symptoms were recorded every morning by the participants in an electronic diary. Mean number of awakenings in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.
| nocturnal awakenings | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | -0.27 ± 0.54 | -0.43 ± 0.89 |
| Week 96 | -0.29 ± 0.58 | -0.49 ± 0.96 |
OCS was allowed as background controller medication for the participants from study EFC13691 only. For this analysis, baseline was defined as parent study EFC13691 baseline.
| percent change | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | 55.32 ± 42.98 | 80.23 ± 30.44 |
| Week 96 | 71.37 ± 29.37 | 88.16 ± 26.83 |
OCS was allowed as background controller medication for the participants from study EFC13691 only. Percentage of participants who achieved a reduction of ≥ 50% in OCS dose were reported.
| percentage of participants | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | 64.9 | 86.0 |
| Week 96 | 82.1 | 94.7 |
OCS was allowed as background controller medication for the participants from study EFC13691 only. Number of participants who gradually discontinued or reduced therapeutic dose were reported in this outcome measure.
| percentage of participants | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | 31.2 | 59.6 |
| Week 96 | 42.9 | 78.9 |
EQ-5D-3L: validated and reliable self-report health status questionnaire consisted of EQ-5D descriptive system and visual analogue scale (VAS). EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem, some problems, and severe problems. The 5 dimensional 3-level systems was converted into single index utility score, and the score was 0 - 100, where 100=best health state; and 0=worst health state; where higher scores indicated better outcome. For this analysis, baseline was defined as parent DRI12544 study baseline.
| score on a scale | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | 0.13 ± 0.20 | 0.14 ± 0.21 |
| Week 96 | 0.12 ± 0.18 | 0.13 ± 0.21 |
EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. For this analysis, baseline was defined as parent DRI12544 study baseline.
| score on a scale | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab |
|---|---|---|
| Week 48 | 10.10 ± 15.40 | 12.88 ± 18.76 |
| Week 96 | 9.90 ± 18.92 | 13.95 ± 18.81 |
Collected over Reported AE and deaths were TEAEs that developed, worsened, or became serious and deaths that occurred during the TEAE period (time from the first dose of dupilumab in LTS12551 up to the last dose of dupilumab plus 14 weeks) (i.e. up to 108 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants From DRI12544 Study Placebo/Dupilumab | 0/111 (0%) | 14/111 (12.6%) | 80/111 (72.1%) |
| Participants From DRI12544 Study Dupilumab/Dupilumab | 3/421 (0.7%) | 42/421 (10%) | 323/421 (76.7%) |
| Participants From EFC13579 Study Placebo/Dupilumab | 0/517 (0%) | 48/517 (9.3%) | 357/517 (69.1%) |
| Participants From EFC13579 Study Dupilumab/Dupilumab | 1/1,013 (0.1%) | 106/1,013 (10.5%) | 666/1,013 (65.7%) |
| Participants From EFC13691 Study Placebo/Dupilumab | 0/97 (0%) | 12/97 (12.4%) | 56/97 (57.7%) |
| Participants From EFC13691 Study Dupilumab/Dupilumab | 0/90 (0%) | 10/90 (11.1%) | 55/90 (61.1%) |
| Participants From PDY14192 Study Placebo/Dupilumab | 0/19 (0%) | 0/19 (0%) | 18/19 (94.7%) |
| Participants From PDY14192 Study Dupilumab/Dupilumab | 0/14 (0%) | 4/14 (28.6%) | 13/14 (92.9%) |
| Event | Participants From DRI12544 Study Placebo/Dupilumab | Participants From DRI12544 Study Dupilumab/Dupilumab | Participants From EFC13579 Study Placebo/Dupilumab | Participants From EFC13579 Study Dupilumab/Dupilumab | Participants From EFC13691 Study Placebo/Dupilumab | Participants From EFC13691 Study Dupilumab/Dupilumab | Participants From PDY14192 Study Placebo/Dupilumab | Participants From PDY14192 Study Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Diaphragmatic HerniaGastrointestinal disorders | 0/111 | 0/421 | 0/517 | 0/1013 | 0/97 | 0/90 | 0/19 | 1/14 |
| Squamous Cell Carcinoma Of SkinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/111 | 0/421 | 0/517 | 0/1013 | 0/97 | 0/90 | 0/19 | 1/14 |
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 0/111 | 2/421 | 0/517 | 0/1013 | 0/97 | 0/90 | 0/19 | 1/14 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 4/111 | 2/421 | 13/517 | 18/1013 | 0/97 | 5/90 | 0/19 | 1/14 |
| PneumoniaInfections and infestations | 3/111 | 4/421 | 4/517 | 7/1013 | 1/97 | 1/90 | 0/19 | 0/14 |
| Acute Coronary SyndromeCardiac disorders | 0/111 | 0/421 | 0/517 | 0/1013 | 0/97 | 1/90 | 0/19 | 0/14 |
| Eosinophilic Granulomatosis With PolyangiitisImmune system disorders | 0/111 | 0/421 | 0/517 | 2/1013 | 1/97 | 1/90 | 0/19 | 0/14 |
| Fibroadenoma Of BreastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/111 | 0/421 | 0/517 | 1/1013 | 0/97 | 1/90 | 0/19 | 0/14 |
| NeuritisNervous system disorders | 0/111 | 0/421 | 0/517 | 0/1013 | 0/97 | 1/90 | 0/19 | 0/14 |
| SyncopeNervous system disorders | 0/111 | 1/421 | 0/517 | 1/1013 | 0/97 | 1/90 | 0/19 | 0/14 |
| Event | Participants From DRI12544 Study Placebo/Dupilumab | Participants From DRI12544 Study Dupilumab/Dupilumab | Participants From EFC13579 Study Placebo/Dupilumab | Participants From EFC13579 Study Dupilumab/Dupilumab | Participants From EFC13691 Study Placebo/Dupilumab | Participants From EFC13691 Study Dupilumab/Dupilumab | Participants From PDY14192 Study Placebo/Dupilumab | Participants From PDY14192 Study Dupilumab/Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Injection Site ErythemaGeneral disorders | 26/111 | 55/421 | 35/517 | 50/1013 | 5/97 | 2/90 | 8/19 | 6/14 |
| NasopharyngitisInfections and infestations | 27/111 | 109/421 | 99/517 | 191/1013 | 17/97 | 16/90 | 3/19 | 6/14 |
| ContusionInjury, poisoning and procedural complications | 3/111 | 14/421 | 12/517 | 14/1013 | 0/97 | 2/90 | 0/19 | 3/14 |
| Back PainMusculoskeletal and connective tissue disorders | 4/111 | 30/421 | 23/517 | 52/1013 | 5/97 | 0/90 | 2/19 | 3/14 |
| VomitingGastrointestinal disorders | 2/111 | 4/421 | 5/517 | 13/1013 | 0/97 | 0/90 | 4/19 | 0/14 |
| HeadacheNervous system disorders | 13/111 | 47/421 | 47/517 | 74/1013 | 4/97 | 5/90 | 4/19 | 1/14 |
| BronchitisInfections and infestations | 15/111 | 80/421 | 63/517 | 117/1013 | 9/97 | 14/90 | 0/19 | 0/14 |
| Upper Respiratory Tract InfectionInfections and infestations | 18/111 | 60/421 | 65/517 | 130/1013 | 8/97 | 6/90 | 2/19 | 0/14 |
| NauseaGastrointestinal disorders | 2/111 | 6/421 | 8/517 | 14/1013 | 0/97 | 0/90 | 3/19 | 1/14 |
| Injection Site OedemaGeneral disorders | 4/111 | 14/421 | 14/517 | 15/1013 | 0/97 | 2/90 | 3/19 | 2/14 |
Analysis was performed on all enrolled participants.
| Age, Customized(Participants) | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| <18 years | 0 | 0 | 32 | 55 | 1 | 1 | 0 | 0 | 89 |
| 18-64 years | 101 | 374 | 422 | 826 | 81 | 80 | 19 | 14 | 1917 |
| 65-74 years | 8 | 40 | 59 | 112 | 14 | 8 | 0 | 0 | 241 |
| 75-84 years | 2 | 7 | 4 | 20 | 1 | 1 | 0 | 0 | 35 |
| ≥85 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 69 | 259 | 335 | 618 | 57 | 53 | 7 | 10 | 1408 |
| Male | 42 | 162 | 182 | 395 | 40 | 37 | 12 | 4 | 874 |
| Race (NIH/OMB)(Participants) | Participants From DRI12544: Placebo/Dupilumab | Participants From DRI12544: Dupilumab/Dupilumab | Participants From EFC13579: Placebo/Dupilumab | Participants From EFC13579: Dupilumab/Dupilumab | Participants From EFC13691: Placebo/Dupilumab | Participants From EFC13691: Dupilumab/Dupilumab | Participants From PDY14192: Placebo/Dupilumab | Participants From PDY14192: Dupilumab/Dupilumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Asian | 18 | 70 | 51 | 116 | 1 | 0 | 0 | 1 | 257 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 3 |
| Black or African American | 1 | 8 | 17 | 43 | 1 | 2 | 2 | 1 | 75 |
| White | 88 | 339 | 445 | 844 | 91 | 86 | 17 | 12 | 1922 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 4 | 9 | 2 | 1 | 0 | 0 | 23 |
Showing the first 100 of 365 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2014 to primary completion in Oct 2019, 62 months.
Results were first posted in Nov 2020, 1 year after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 62 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab